Cargando…

400. Secondary Infections in COVID-19 Patients Receiving Tocilizumab in a Community Hospital

BACKGROUND: Secondary bacterial/fungal infection in patients with pandemic strains of Influenza has been well documented in the literature. Little is known about the development of secondary bacterial or fungal infections in patients with COVID-19. Additionally, COVID patients receiving tocilizumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Usiak, Shauna, DiFilippo, Laurie, Frattellone, Meredith, Kincart, Mary, Kerr, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778001/ http://dx.doi.org/10.1093/ofid/ofaa439.595

Ejemplares similares

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia
por: Warner, Adam, et al.
Publicado: (2021)

341. Evaluation of Antimicrobial Use and Prescribing Patterns During the COVID-19 Pandemic in Patients Receiving Tocilizumab
por: Barsoum, Barbara, et al.
Publicado: (2021)

551. Remdesivir and Tocilizumab for the Treatment of Severe COVID-19 in a Community Hospital: A Retrospective Cohort Study
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

1429. Temperature and Humidity Variations in the Operating Room: A Risk Assessment
por: Usiak, Shauna, et al.
Publicado: (2023)

2390. Acquisition of Clostridium difficile Infection Following Exposure from Roommate Defined by Concordance on Genotyping
por: Aslam, Anoshé, et al.
Publicado: (2019)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

550. Clinical impact of Tocilizumab therapy in SARS-CoV-2 respiratory infections in ICU and non-ICU patients
por: Vyas, Nikunj M, et al.
Publicado: (2020)

566. Tocilizumab: A Friend or a Foe in COVID-19 Management?
por: Hernandez, Jarelys M, et al.
Publicado: (2020)

913 Impact of change in SSI surveillance definition on HPRO among patients with cancer
por: Usiak, Shauna C, et al.
Publicado: (2014)

564. Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19
por: Colgrove, Robert, et al.
Publicado: (2020)

565. Tocilizumab Use in COVID-19: Act(emra) to Inhibit Intubation and Decompensation
por: Willner, Debra M, et al.
Publicado: (2020)

304. Impact of Antibiotic Prophylaxis Prior to Treatment with Steroids and Tocilizumab in COVID-19 Patients
por: de Novales, Francisco Javier Membrillo, et al.
Publicado: (2021)

554. Early Clinical Outcomes with Tocilizumab for Covid-19: A Two-Center Retrospective Study
por: Smoke, Steven, et al.
Publicado: (2020)

297. Infectious Complications Associated with Tocilizumab Use in Patients Infected with SARS-CoV-2 at a Mid-Atlantic Hospital Consortium
por: Kent, Kristen R, et al.
Publicado: (2021)

562. Tocilizumab for the Treatment of Severe COVID-19: A Retrospective, Multi-Center, Case-Matched Series
por: Norman, Sarah, et al.
Publicado: (2020)

539. Impact of Corticosteroids when Combined with Tocilizumab or Remdesivir for the Treatment of Severe SARS-CoV-2
por: Rosati, Michael, et al.
Publicado: (2021)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

553. Outbreak of Methicillin-Resistant Staphylococcus aureus Associated with Hepatic Artery Infusion Pumps
por: Calero, Christopher, et al.
Publicado: (2019)

400. Impact of SARS-CoV-2 Test-based Strategy to Reduce Quarantine Days Among Asymptomatic Healthcare Workers After Household Exposure
por: Navalkele, Bhagyashri D, et al.
Publicado: (2021)

P25 An opportunity for antimicrobial stewardship? Assessing the diagnosis and treatment of lower urinary tract infections among inpatients aged 65 and older in a large English teaching hospital
por: Henry, Shauna, et al.
Publicado: (2022)

562. Tocilizumab Use in the Second Trimester Pregnant Patients with Severe Covid-19 Pneumonia and their Maternal and Fetal Outcomes: Two Case Reports
por: iqbal, Fatima, et al.
Publicado: (2021)

534. The Use of Tocilizumab and Remdesivir in SARS- CoV-2 Patients in El Paso Texas: A Longitudinal Comparative Observational Study
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

682. Is There a Role for the Early Use of Tocilizumab and Interleukin-6 Levels in the Management of SARS-CoV-2 Patients with Early Respiratory Failure?
por: Antony, Suresh J, et al.
Publicado: (2020)

ML-13 Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab
por: Ohno, Masasuke, et al.
Publicado: (2021)

400. Rehospitalization of Patients for Recurrent Clostridioides difficile Infection
por: Drwiega, Emily, et al.
Publicado: (2022)

528. Hospital Course of Patients Receiving Bamalanivimab: A Real World Analysis
por: Belk, Madeline, et al.
Publicado: (2021)

1403. The Pediatric Emergency Room as a Promising Setting for Receiving the Flu Shot
por: Miller, Christine M, et al.
Publicado: (2020)

109. Develop and Implement a Novel Pediatric Antimicrobial Stewardship Program in a Non-Freestanding Children’s Hospital Located in an Adult-Centered Community Hospital in San Joaquin Valley, California
por: Lien, Tsung-Chi, et al.
Publicado: (2021)

Abstract 36: Management of Primary and Secondary Lymphedema: Analysis of 400 Referrals to a Center
por: Maclellan, Reid A., et al.
Publicado: (2017)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

149. Unmet Informational Needs among Nursing Home Residents Receiving Antibiotics: A Qualitative Study
por: Carter, Eileen, et al.
Publicado: (2020)

909 Comparison of three different data sources for Surgical Site Infection (SSI) Surveillance after Colon Surgery
por: Childers, Teresa, et al.
Publicado: (2014)

Accidental withdrawal of catheters in 400 patients in ICU
por: Lorente, L, et al.
Publicado: (2002)

807. Effect of Inter-Hospital Transfer on Nosocomial Infection Rates in Patients Receiving Extracorporeal Membrane Oxygenation
por: Marcus, Joseph E, et al.
Publicado: (2020)

1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia
por: Katsube, Takayuki, et al.
Publicado: (2020)

232. Impact of Weekend Initiation of Vancomycin or Piperacillin/Tazobactam on Days of Therapy Received upon Hospital Admission
por: McGregor, Jessina C, et al.
Publicado: (2020)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fe8nj7hgs6fphgdop9dcc0nrja